NCT06272786

Brief Summary

Suprascapular nerve block is an injection method that has been shown to be effective in shoulder rehabilitation in diseases such as adhesive capsulitis and stroke .. Applying the block under USG guidance instead of blinding increases the effectiveness and reduces complications.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 13, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 22, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

July 28, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

August 2, 2024

Status Verified

August 1, 2024

Enrollment Period

6 months

First QC Date

February 13, 2024

Last Update Submit

August 1, 2024

Conditions

Keywords

Rotator Cuff Tearspainnerve blockrehabilitation

Outcome Measures

Primary Outcomes (6)

  • Visual Analog Scale (VAS)

    In the study, pain intensity was evaluated with the Visual Analogue Scale (VAS). Numbers from 0 to 10 on VAS; Patients will be asked to score their pain levels at rest, activity and at night, with 0 being defined as "no pain" and 10 being "unbearable pain". Increased scores indicate higher pain intensity.

    Baseline

  • Visual Analog Scale (VAS)

    In the study, pain intensity was evaluated with the Visual Analogue Scale (VAS). Numbers from 0 to 10 on VAS; Patients will be asked to score their pain levels at rest, activity and at night, with 0 being defined as "no pain" and 10 being "unbearable pain". Increased scores indicate higher pain intensity.

    6th week

  • Visual Analog Scale (VAS)

    In the study, pain intensity was evaluated with the Visual Analogue Scale (VAS). Numbers from 0 to 10 on VAS; Patients will be asked to score their pain levels at rest, activity and at night, with 0 being defined as "no pain" and 10 being "unbearable pain". Increased scores indicate higher pain intensity.

    10th week

  • Shoulder joint range of motion (ROM)

    Joint range of motion will be measured and recorded passively in all directions using a goniometer according to the neutral zero method.

    Baseline

  • Shoulder joint range of motion (ROM)

    Joint range of motion will be measured and recorded passively in all directions using a goniometer according to the neutral zero method.

    6th week

  • Shoulder joint range of motion (ROM)

    Joint range of motion will be measured and recorded passively in all directions using a goniometer according to the neutral zero method.

    10 th week

Secondary Outcomes (6)

  • Shoulder Pain and Disability Index (SPADİ)

    Baseline

  • Shoulder Pain and Disability Index (SPADİ)

    6th week

  • Shoulder Pain and Disability Index (SPADİ)

    10th week

  • Modified Constant-Murley Scoring

    6th week

  • Modified Constant-Murley Scoring

    10th week

  • +1 more secondary outcomes

Study Arms (2)

Experimental Group

EXPERIMENTAL

In addition to the conventional physiotherapy program, patients in the intervention group will receive a suprascapular nerve block with musculoskeletal USG guidance available in our clinic at the beginning of rehabilitation. Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.

Procedure: conventional physiotherapy program.Procedure: Suprascapular nerve block

Control Group

ACTIVE COMPARATOR

Patients in the control group will only receive a conventional physiotherapy program.

Procedure: conventional physiotherapy program.

Interventions

It will be applied to a rehabilitation program including joint range of motion exercises and physical therapy modalities by a physiotherapist at the Physical Therapy Hospital.

Control GroupExperimental Group

Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.

Experimental Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Having undergone arthroscopic rotator cuff repair surgery within the last week

You may not qualify if:

  • History of previous surgery on the same shoulder
  • History of systemic inflammatory rheumatological disease
  • Neurological diseases with muscle weakness in the upper extremity (MS, ALS, Muscular -Dystrophy)
  • History of malignancy, pregnancy, breastfeeding
  • Use of steroids or immunosuppressive drugs
  • History of allergic reactions to local analgesics
  • Fibromyalgia syndrome
  • Chronic painful conditions that require opioid use
  • Presence of known psychiatric disease
  • Cognitive impairment (Mini Mental Test Score \<23)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahi Evran University

Kirşehir, City Centre, 40100, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Rotator Cuff InjuriesPain

Condition Hierarchy (Ancestors)

RuptureWounds and InjuriesShoulder InjuriesTendon InjuriesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Basak Cigdem Karacay, Asst Prof

    Kirsehir Ahi Evran University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Basak Cigdem Karacay, Asst Prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Investigator and outcome assessor will be different persons.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomised controlled
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 13, 2024

First Posted

February 22, 2024

Study Start

July 28, 2024

Primary Completion

February 1, 2025

Study Completion

March 1, 2025

Last Updated

August 2, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations